Avenue Therapeutics files U.S. application for IV tramadol; shares up 2%


Avenue Therapeutics (ATXI +1.9%) has submitted a marketing application to the FDA seeking approval of lead drug IV tramadol, a dual-acting opioid, for the management of moderate-to-moderately severe pain in adults in a supervised healthcare setting.





READ SOURCE

READ  Sebi eases buyback norms for companies with housing finance, NBFC arms

LEAVE A REPLY

Please enter your comment!
Please enter your name here